Showing results (101-110 of 187) with videos related to

Sort By:
Pageof 19
Blood Advances|July 19, 2023
Early cessation of calcineurin inhibitors is feasible post-haploidentical blood stem cell transplant: the ANZHIT 1 studyJohn Moore, Nada Hamad, David Gottlieb, et al.
European Journal of Haematology|May 3, 2018
Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabineAshvind Prabahran, Mark Tacey, Shaun Fleming, et al.
Frontiers in Immunology|October 21, 2017
Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune ProfilingBenjamin W Teh, Simon J Harrison, Cody Charles Allison, et al.
Frontiers in Immunology|November 25, 2017
Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell TransplantationMichelle K Yong, Paul U Cameron, Monica A Slavin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load MonitoringMichelle K Yong, Michelle Ananda-Rajah, Paul U Cameron, et al.
Integrative Cancer Therapies|March 1, 2024
Evaluating the Feasibility and Acceptability of a Psychosexual Intervention for Couples Post-allogeneic Hematopoietic Stem Cell TransplantationBrindha Pillay, David Ritchie, Yvonne Panek-Hudson, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 14, 2012
A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantationAmit Khot, Michael Dickinson, Kerrie Stokes, et al.
Leukemia|February 5, 2021
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemiaAndrew H Wei, Josep-Maria Ribera, Richard A Larson, et al.
The Lancet. Haematology|February 1, 2023
Treatment approaches for patients with TP53-mutated mantle cell lymphomaThomas E Lew, Adrian Minson, Michael Dickinson, et al.
Internal Medicine Journal|June 6, 2022
Predictors and outcomes of dose reduction of methotrexate and cyclosporin graft-versus-host disease prophylaxis following allogeneic haemopoietic cell transplantationRadha Ramanan, Andrew B M Lim, Joanne L C Tan, et al.
Pageof 19